Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Silence Therapeutics plc

NASDAQ: SLN · Life Sciences · 3 alerts · CIK 1479615

Share price
$19.80Close, Nov 16
Market cap
$3.69B
Shares outstanding
186.61MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Silence Therapeutics plc filings on SEC EDGAR ↗

6:03 AM ET 10-Q
Financial Results

Silence Therapeutics Q3 2026 Results: Net Loss of $12.4M, Loss Narrows

Silence Therapeutics reported a net loss of $39.7 million for the nine months ended September 30, 2026, a significant improvement from the $76.8 million loss in the prior year period. The company strengthened its balance sheet through a major share issuance in the third quarter, bringing cash and cash equivalents to $247.7 million, which management believes will fund operations until at least 2028.

Key figure
Net loss $12.4M
8:10 AM ET 8-K
M&A Deal

Silence Therapeutics M&A Deal with Merck KGaA

Silence Therapeutics announced it has entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany. The transaction is expected to close in the first quarter of 2027, subject to customary closing conditions and shareholder approval. While the filing also contains Q3 2026 financial results, the pending acquisition is the primary material event for investors.

Counterparty
Merck KGaA
8:06 AM ET 8-K
M&A Deal

Silence Therapeutics Signs $1.3B M&A Deal with Merck KGaA, Darmstadt, Germany

Silence Therapeutics has entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany for approximately $1.3 billion in cash. Under the terms of the deal, Silence shareholders will receive $20.00 per ADS, representing a 130% premium to the company's recent closing price. The acquisition aims to strengthen Merck KGaA's specialty and rare disease pipeline, specifically incorporating Silence's Phase 2 siRNA candidate, Divesiran.

Value
$1.3B
Counterparty
Merck KGaA, Darmstadt, Germany

“We are pleased to have reached this agreement with Merck KGaA, Darmstadt, Germany, which is the result of a competitive sale process and delivers significant, immediate and certain value to our shareholders.”

Iain Ross, Interim Principal Executive Officer and Chairman of the Silence Board

“The planned acquisition of Silence Therapeutics will strengthen our capabilities to serve patients with targeted specialty and rare diseases.”

Kai Beckmann, Chairman of the Executive Board and Group CEO of Merck KGaA, Darmstadt, Germany

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.